Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

LG100754

LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR[1].

Product Specifications

CAS Number

[180713-37-5]

Product Name Alternative

UVI 2112

UNSPSC

12352005

Target

RAR/RXR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lg100754.html

Purity

99.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C/C(C1=C(OCCC)C=C2C(C)(C)CCC(C)(C)C2=C1)=C/C=C/C(C)=C/C(O)=O

Molecular Formula

C26H36O3

Molecular Weight

396.56

References & Citations

[1]Cesario RM, et al. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15 (8) :1360-9.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

PPARα; PPARγ

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Mmu-miR-7679-5p antagomir
HY-RI04109A-01 5 nmol

Mmu-miR-7679-5p antagomir

Ask
View Details
Mmu-miR-7679-5p antagomir
HY-RI04109A-02 20 nmol

Mmu-miR-7679-5p antagomir

Ask
View Details
MEIS3 Peptide - middle region
MBS3233645-01 0.1 mg

MEIS3 Peptide - middle region

Ask
View Details
MEIS3 Peptide - middle region
MBS3233645-02 5x 0.1 mg

MEIS3 Peptide - middle region

Ask
View Details
Human CSPP1 ELISA KIT
ELI-50488h 96 Tests

Human CSPP1 ELISA KIT

Ask
View Details
Mouse Monoclonal USP9x Antibody (OTI2G7) [Alexa Fluor 594]
NBP2-74822AF594 0.1 mL

Mouse Monoclonal USP9x Antibody (OTI2G7) [Alexa Fluor 594]

Ask
View Details